Cargando…
Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma
BACKGROUND: Pancreatic cancer has a 5-year survival rate of only 5–7%. Difficulties in detecting pancreatic cancer at early stages results in the high mortality and substantiates the need for additional diagnostic tools. Surgery is the only curative treatment and unfortunately only possible in local...
Autores principales: | Henriksen, Stine Dam, Madsen, Poul Henning, Larsen, Anders Christian, Johansen, Martin Berg, Drewes, Asbjørn Mohr, Pedersen, Inge Søkilde, Krarup, Henrik, Thorlacius-Ussing, Ole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112622/ https://www.ncbi.nlm.nih.gov/pubmed/27891190 http://dx.doi.org/10.1186/s13148-016-0286-2 |
Ejemplares similares
-
Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma
por: Henriksen, Stine Dam, et al.
Publicado: (2017) -
Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma
por: Stubbe, Benjamin Emil, et al.
Publicado: (2021) -
Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma
por: Stubbe, Benjamin Emil, et al.
Publicado: (2023) -
The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer
por: Rasmussen, Simon Ladefoged, et al.
Publicado: (2018) -
Hypermethylated DNA, a circulating biomarker for colorectal cancer detection
por: Rasmussen, Simon Ladefoged, et al.
Publicado: (2017)